HRTX Heron Therapeutics Inc

$HRTX Got my PACER account cleared. Here's a summary of Heron's opening brief and their main arguments. To me, the most compelling argument is #3. Apparently, through the entire trial. Bryson interpreted the claims one way, and then literally changed the interpretation 180 degrees after the trial proceedings were done. Heron was not given a chance to argue the new interpretation, not to mention that the new interpretation goes completely against precedence as well as Bryson's own interpretation in the Fresenius case. This country needs to put in a law that people over 80 cannot not serve in public office. They really do f--- it all up.

$HRTX Someone should knock on the gates of the Bryson Palazzo to see if he is still kickin. No decision yet on the emergency stay order. Tomorrow is the deadline for Heron to file their opening brief for the appeal. Given Bryson's MIA status, they will almost assuredly file the operning brief along with escalating the emergency stay order to the appellate court under the defacto denial/constructive delay clause. From there, it's technically ~25 days before the final ruling on the emergency stay, whatever it might be, goes into effect. This is all just horribly painful.

$HRTX Despite the company’s tremendous product potential, this has been a deeply disappointing investment. Management has repeatedly eroded shareholder confidence through vague communication, delayed updates, weak execution, shifting priorities, and inadequate planning. The company has failed to convert its scientific promise into timely commercial progress or anticipate operational challenges. The recent decision to explore “strategic alternatives” is especially frustrating. Given the prolonged underperformance and mounting risks, this process should have begun much earlier, when the balance sheet and strategic flexibility were stronger. The products may still have significant potential, but poor communication, weak execution, and delayed decision-making have made this an exceptionally frustrating investment. I look forward to an end after many years of disappointment. Two lessons for me : No more biotech stocks and only invest in companies with good management.

$HRTX We talked about how Kevin Tang added a ton of HRTX to his holdings earlier this year, to bring his share total to 6,250,000 , and enough folks know some of his history, with Concentra being his vehicle for buyouts. But, what hasn't been discussed here is that Kevin Tang has a long history with Heron Therapeutics, one that goes far beyond just an ordinary, or even extraordinarily close, association. Kevin Tang actually co-founded Heron Therapeutics, Inc. in 2009, served as Director from 2009 to 2012, and Chairman from 2012 to 2020, so it would not come as a surprise to find that Tang's radar is locked onto Heron Therapeutics, and for those who aren't familiar with how Kevin Tang operates, you can simply research his history and that of his Concentra operation Chew on this for a while, after researching Kevin Tang's tactics and M&A history.. . . .

$HRTX it feels shorts are pushing this stock lower to buy themselves moretime while big boys are taking this unique opportunity to accumulate without pushing stocks up. This is like a spring compressed to its limit, and when it finally releases , the move could be colossa. agree with taco Tick tock, tick tock

$HRTX Did the FUD puppet eat a bad oyster, or did he get reassigned? None of his Stocktwits accounts have chimed in lately.... LOL . . .

$HRTX Odds of a short SQUEEZE are higher with the FUD puppet saying otherwise, no different than when Goldman is buying while they're telling everyone to sell . .

$HRTX I love seeing the fear among those short sellers; they’re the ones who tanked Heron’s price, and now they’re the ones terrified. I just want to remind them—in case they’ve forgotten—that those 46–50 million borrowed shares have to be returned, or a margin call will force their hand... assuming, of course, that anyone is actually willing to sell at these garbage prices. Hahahaha.

$HRTX Since folks are wondering whether Heron ever filed a motion for emergency stay pending appeal. If you have access to PACER, you can download the entire PDF.

$HRTX HRTX doesn’t need CINVANTI to grow forever. It needs enough time for ZYNRELEF and APONVIE to become large enough to carry the business. And that’s the part I’d watch very closely over the next 2–3 quarters. Still long and worth the risk!

$HRTX my hypothetical speculation contd 2/2 Even though heron appeared to be distressed right now, a buyer (more preferrably) a big pharma will consider the potential value of the company and how much income they can generate from buying the company. Heron has pharma assets that work and are selling, Big pharma can easily 5-10x that income generated for way cheaper cost with their already established structure. I have seen big pharmas buy many companies in phase 1 and phase 2 trials for loads of cash. Heron is in way more better position than those companies generating zero income being bought out.

$HRTX People on here are finally realizing the obvious and have stopped posting their nonsense. Heron will continue to move sideways until next earnings unless there is a buyout or positive news on cinvanti. That good news can happen, but everyone should be prepared for it not to happen. Continue to hope for a buyout of any kind just to end the misery. I doubt if the next earnings report will change anything in a positive direction. Even though heron is not dropping significantly, everyone invested in it is losing money because their money could grow if invested in better stocks. The only reason to stick with heron is because of its insanely low price and the chance for a buyout of any kind. That is the only reason I remain a shareholder.

$HRTX Collard was supposed to be our savior! Instead he has all but killed Heron and paid him and his cronies a ton of money to destroy this company. We better hear of a plan soon! He stated numerous times that his job was to bring equity to the shareholders.  He has failed miserably Sadly, these are just the facts

$HRTX I find it baffling that we are currently sitting on a 59M Market Cap. That makes this stock down almost 80% since inception of CEO Collard. Not sure if any of us assholes who actually invested in this stock could have done a better job. This team has never pivoted from colossal mistake that hiring crosslink was going to increase sales. big failure. If this team had any inkling that Cinvanti patent was in jeopardy why did it take so long to hire more sales rep for acute care. Another error. What the fuck has the Board and CEO been doing last 3 years besides pissing down our back and telling us it is raining. We are here now because last 2 quarters have seen 2 bakd revenue misses. Couldnt blame weather for last quarter, why the hell did you keep year end guidance if you new revenue was not growing as expected, i can contin ue by why bother at this point

$HRTX I cant believe I sold my IOVA shares and bought this POS! My IOVA investment would have doubled within 3-4 weeks! What a shame!

$HRTX I hope they halt the stock and release the decision today. Either way give us something before the long weekend! Cheers

$HRTX if some people paid attention, I actually called IOVA before it squeezed. I am not an expert, but my DD was a good one on that. Not saying I cannot be wrong (who can't). But my DD and instinct calls this a big winner. Like I said I am not a financial advisor or a professional, but I will just keep accumulating this pos.

$HRTX CINVANTI → strategic transaction ↓ Debt↓ / liquidity ↑ ↓ ZYNRELEF growth continnues ↓ PFS approval ↓ ex-US partner/s ↓ royalties + milestones ↓ ZYNRELEF becomes main asset of HERON

$HRTX maybe something was different today usually it gives back the gains before the close it stayed strong interesting. See if it continues tomorrow.

$HRTX To the short sellers: it’s pointless spreading fear-mongering news here without any data to back it up. Institutions have already locked up 80.55% of Heron shares—not to mention the holdings of insiders who never sell—so the very limited free float won't be enough for you to cover your borrowed positions. You’d be better off preparing for the 43–50 million shares you owe and need to return. Hahahaha.